Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.

Antiviral therapy - 1 Jan 2015

Geipel Andreas, Seiz Pia L, Niekamp Hauke, Neumann-Fraune Maria, Zhang Ke, Kaiser Rolf, Protzer Ulrike, Gerlich Wolfram H, Glebe Dieter

Abstract excerpt

BACKGROUND: Entecavir is an efficient inhibitor of HBV reverse transcriptase (RT) and widely used for therapy of chronic hepatitis B. Entecavir treatment of HBV patients with lamivudine-resistant viral strains, however, often fails, but the mechanism of cross-resistance development is not fully understood. METHODS: Using non-linear regression models, dose-response curves of cloned HBV strains from patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Guanine

Share to Hepatitis B

Share to Hepatitis B virus

Share to Inhibitory Concentration 50

Share to Lamivudine

Share to Virus Replication

Source

Identifiers

PMID: 25560463
DOI: 10.3851/IMP2928

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Entecavir allows an unexpectedly high residual replication of HBV mutants resistant to lamivudine.PMID 25560463Read ↗

Successful treatment of an entecavir-resistant hepatitis B virus variant.Semantic proximity Read ↗

Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?Semantic proximity Read ↗

The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus.Semantic proximity Read ↗

Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.Semantic proximity Read ↗

Impact of lamivudine-resistance mutations on entecavir treatment outcome in hepatitis B.Semantic proximity Read ↗

Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistanceSemantic proximity Read ↗

Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.Semantic proximity Read ↗

Multiple drug-resistant HBV mutation may contribute to poor response of adefovir + entecavir in entecavir-resistant patients.Semantic proximity Read ↗

Evolution of hepatitis B virus mutation during entecavir rescue therapy in patients with antiviral resistance to lamivudine and adefovir.Semantic proximity Read ↗

Characterization of novel entecavir resistance mutations.Semantic proximity Read ↗

Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.Semantic proximity Read ↗

Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.